Jarvis L M, Davidson F, Hanley J P, Yap P L, Ludlam C A, Simmonds P
Department of Medical Microbiology, University of Edinburgh, UK.
Lancet. 1996 Nov 16;348(9038):1352-5. doi: 10.1016/s0140-6736(96)04041-x.
Hepatitis G virus (HGV or GBV-C) is a newly discovered human flavivirus distantly related to hepatitis C virus (HCV). Little information is available on its natural history or routes of transmission, although it can be transmitted parenterally. We investigated the prevalence of persistent infection of HGV and HCV in patients exposed to non-virus-inactivated pooled blood products associated with transmission of HCV.
RNA was extracted from the plasma of 112 patients with haemophilia and 57 with hypogammaglobulinaemia, as well as from 64 different batches of archived coagulation-factor concentrates and immunoglobulins. RNA was reverse transcribed and amplified with primers from the 5' non-coding region of HCV and HGV by a nested polymerase chain reaction (PCR). Viral RNA was quantified by titration of complementary DNA before amplification.
Among non-renumerated UK blood donors HGV infection (detected by PCR) was more common than HCV infection (four [3.2%] of 125 compared with 137 [0.076%] of 180658 in southeast Scotland). Testing of batches of factor VIII and factor IX concentrates prepared without viral inactivation procedures showed high frequencies of contamination with HGV (16 of 17 factor VIII batches positive; six of six factor IX batches positive), with no difference between renumerated and non-renumerated donors. However, among 95 haemophiliacs who had received non-virus-inactivated concentrates, 13 (14%) were positive for HGV compared with 79 (83%) who were positive for HCV. Two of 37 recipients of long-term immunoglobulin replacement therapy were positive for HGV. Virus inactivation of blood products substantially reduced or eliminated contamination by HGV RNA sequences.
Despite the extremely high level of HGV contamination of non-virus-inactivated blood products, their use was not associated with high rates of persistent infection in recipients. The infectivity of HGV in blood products may be lower than that of HCV, or the virus may be less able to establish persistent infection in humans. Whatever the case, the high prevalence of active HGV infection in the general population remains difficult to explain.
庚型肝炎病毒(HGV或GBV - C)是一种新发现的人类黄病毒,与丙型肝炎病毒(HCV)有较远的亲缘关系。尽管它可通过肠道外途径传播,但其自然史或传播途径的信息却很少。我们调查了接触与HCV传播相关的未灭活混合血液制品的患者中HGV和HCV持续感染的患病率。
从112例血友病患者和57例低丙种球蛋白血症患者的血浆中提取RNA,以及从64个不同批次的存档凝血因子浓缩物和免疫球蛋白中提取RNA。RNA经逆转录后,使用来自HCV和HGV 5'非编码区的引物,通过巢式聚合酶链反应(PCR)进行扩增。在扩增前,通过滴定互补DNA对病毒RNA进行定量。
在英国无偿献血者中,HGV感染(通过PCR检测)比HCV感染更常见(125例中有4例[3.2%],而苏格兰东南部180658例中有137例[0.076%])。对未经过病毒灭活程序制备的VIII因子和IX因子浓缩物批次进行检测发现,HGV污染频率很高(17个VIII因子批次中有16个阳性;6个IX因子批次中有6个阳性),有偿献血者和无偿献血者之间没有差异。然而,在95例接受未灭活浓缩物的血友病患者中,13例(14%)HGV呈阳性,而79例(83%)HCV呈阳性。37例接受长期免疫球蛋白替代治疗的患者中有2例HGV呈阳性。血液制品的病毒灭活显著减少或消除了HGV RNA序列的污染。
尽管未灭活血液制品中HGV污染水平极高,但使用这些制品并未导致接受者中持续性感染的高发生率。血液制品中HGV的传染性可能低于HCV,或者该病毒在人体内建立持续性感染的能力可能较低。无论哪种情况,普通人群中活动性HGV感染的高患病率仍然难以解释。